Alere has recalled 803,000 of its Triage tests after problems with quality control testing and performance of the diagnostics. The recall affects a total of 104 lots comprising 287,000 Alere Triage BNP (B-type natriuretic peptide) tests, 46,000 Alere Triage D-dimer tests and 470,000 Alere Triage cardiology panel tests, according to a company filing with the US Securities and Exchange Commission (SEC).
It looks like the company will also have to recall its Alere Triage TOX Drug Screen test: it said it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?